Histone demethylase GASC1 - a potential prognostic and predictive marker in invasive breast cancer

BMC Cancer

Table 6 GASC1 and survival of breast cancer patients according to the type of adjuvant treatment

Cases	n	RFS			BCSS			OS
		HR	95% CI	p*	HR	95% CI	p*	HR	95% CI	p*
radiotherapy	206
negative	119	1§			1§			1§
positive	87	0.52	0.33 to 0.83	0.006	0.49	0.29 to 0.82	0.007	0.71	0.47 to 1.06	0.097
tamoxifen	62
negative	25	1†			1†			1†
positive	37	0.45	0.21 to 0.99	0.048	0.33	0.13 to 0.81	0.015	0.66	0.34 to 1.29	0.23
chemotherapy	69
negative	43	1‡			1‡			1‡
positive	26	0.64	0.29 to 1.38	0.25	0.70	0.30 to 1.64	0.41	0.81	0.36 to 1.82	0.60

RFS = relapse-free survival; BCSS = breast cancer specific survival; OS = overall survival.
*p was based on Cox proportional analysis.
§Reference value; HRs adjusted for age and stage at diagnosis, chemotherapy, hormonal treatment and hormone receptor status.
†Reference value; HRs adjusted for age and stage at diagnosis and radiotherapy.
‡Reference value; HRs adjusted for age and stage at diagnosis, radiotherapy and hormone receptor status.

ISSN: 1471-2407